MedTrace Logo

Careseng 1370 for Chemotherapy-Induced Myelosuppression

NCT03692780 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2018-12-17

No results posted yet for this study

Summary

This is a Phase I/IIa dose-finding (Phase I) followed by randomized, double-blind, placebo-controlled, parallel, add-on to cisplatin + docetaxel (Phase IIa) study to evaluate the safety, tolerability, and efficacy profiles of Careseng 1370 in subjects with advanced NSCLC.

Conditions

  • Chemotherapy-Induced Myelosuppression

Interventions

DRUG

Careseng 1370

4,000mg granules in sachet

DRUG

Placebo

4,000mg granules in sachet

Sponsors & Collaborators

  • Careseng Biotech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-31
Primary Completion
2021-03-31
Completion
2021-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03692780 on ClinicalTrials.gov